Funder: National Institutes of Health

Due Dates: June 4, 2025 (Application) | May 5, 2025 (Letter of Intent) | September 7, 2025 (AIDS) | October 2, 2025 (Application) | January 7, 2026 (AIDS) | February 3, 2026 (Application) | June 4, 2026 (Application) | September 7, 2026 (AIDS) | October 2, 2026 (Application) | January 7, 2027 (AIDS)

Funding Amounts: Up to $250,000 direct costs/year (R61, up to 2 years); up to $1,515,000 direct costs/year (R33, up to 3 years); max 5 years total.

Summary: Supports investigator-initiated, Phase I clinical trials for diagnostic or therapeutic interventions in heart, lung, blood, and sleep disorders, including final-stage preclinical activities.

Key Information: Bi-phasic, milestone-driven R61/R33 mechanism; animal studies not allowed; only Phase I trials eligible.